Clinical trial · Observational
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)
NCT03655015CI-TRIAL-00108830recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Create a living biobank of PDOs from Stage I-III lung cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasm | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lung Tumor Resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.
- timeFrame
- 10 years
- description
- Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism
Secondary outcomes (1)
- measure
- Correlation of PDO and Circulating tumor cells (CTCs)
- timeFrame
- 10 years
- description
- To establish a connection between PDOs and CTCs, and their relationship to cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure. * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care * Any clinical stage of lung cancer * Adult patients ≥18 years of age * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history Exclusion Criteria: * At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
References
Publications (0)
Data not yet available
No reference posted for this study.